4Chris B, Elke-Astrid A, Gary F, et al. Peroxisome proliferator-activated receptor agonist provides superior renal protection versus angiotensin-convetting enzyme Inhibition in a rat model of type 2 diabetes with obesity. Pharmacol Experi Therau, 2003,307:854-860.
5Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol,2001,106 : 148-156.
6Amemiya T, Sasamura H , Mifune M, et al. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int, 1999,56 : 2055-2063.
7Thoralf M, Nozomu T, Guo SC,et al. RAGE drives the development of glomeruloselerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Path, 2003,162 : 1123-1135.
8Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation ,2002,105:373-379.
9Hoshi S, Shu Y, Yonshida F, et al. Podocyte injury promotes progressive nephropathy in zueker diabetic fatty rats. Lab Invest,2002,82:25-35.
10Tsuehida K, Makita Z, Yamagishi S. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephroPathy in rats by a novel advanced glycaton and product inhibitor, OPB-9195. Diabetologia, 1999,42:579-588.
